Cargando…

Facing challenges with hope: universal immune cells for hematologic malignancies

Many patients have achieved a favorable overall survival rate since allogenic hematopoietic stem cell transplantation (allo-HSCT) has been widely implemented to treat hematologic malignancies. However, graft-versus-host disease (GVHD) and complications of immunosuppressive drugs after allo-HSCT are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yuqing, Huang, Ruihao, Wang, Zheng, Xiong, Jingkang, Wang, Xiaoqi, Zhang, Xi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157807/ https://www.ncbi.nlm.nih.gov/pubmed/37144558 http://dx.doi.org/10.20892/j.issn.2095-3941.2022.0759

Ejemplares similares

Strategies to enhance CAR-T persistence
por: Liu, Yue, et al.
Publicado: (2022)

CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022
por: Huang, Ruihao, et al.
Publicado: (2023)

CAR-NK cell therapeutics for hematologic malignancies: hope is on the horizon
por: Xu, Kai-lin, et al.
Publicado: (2019)

Cellular immunotherapy as a beacon of hope for hematological malignancies
por: Lee, Hyun-Ju, et al.
Publicado: (2015)

COVID-19 in Hematologic Malignancies: Big Challenges
por: Hu, Yongxian, et al.
Publicado: (2020)

Current status and prospects of hematopoietic stem cell transplantation in China
por: Wang, Xiaoqi, et al.
Publicado: (2022)

The Challenge of Targeting Notch in Hematologic Malignancies
por: Hernandez Tejada, Fiorela N., et al.
Publicado: (2014)

Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin
por: Ghetti, Martina, et al.
Publicado: (2020)

Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future
por: Zhang, Zeng, et al.
Publicado: (2022)

Immune Therapies for Hematologic Malignancies
por: Olnes, Matthew J.
Publicado: (2021)

Immune Microenvironment in Hematologic Malignancies
por: Arandi, Nargess, et al.
Publicado: (2023)

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
por: Wang, Hao, et al.
Publicado: (2019)

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
por: Tang, Lu, et al.
Publicado: (2023)

Genetically engineered pigs for xenotransplantation: Hopes and challenges
por: Xi, Jiahui, et al.
Publicado: (2023)

Ginsenoside Rg1 improves anti-tumor efficacy of adoptive cell therapy by enhancing T cell effector functions
por: Liu, Yue, et al.
Publicado: (2023)

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2020)

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
por: Zhao, Zijun, et al.
Publicado: (2018)

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
por: Zhang, Xiaomin, et al.
Publicado: (2022)

Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020)

Microsatellite instability in hematological malignancies: Hypermutation vs. immune control—who is challenging who?
por: Maletzki, Claudia, et al.
Publicado: (2013)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
por: Yang, Guancui, et al.
Publicado: (2022)

Deubiquitinases in hematological malignancies
por: Lei, Hu, et al.
Publicado: (2021)

Challenges and optimal strategies of CAR T therapy for hematological malignancies
por: Zhang, Yajing, et al.
Publicado: (2023)

Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
por: Lamb, Margaret G., et al.
Publicado: (2021)

The hope of immunity
por: Lawton, Graham
Publicado: (2020)

2113. Infectious endocarditis in patients with hematologic malignancy at the University of Wisconsin
por: Scolarici, Michael J, et al.
Publicado: (2022)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
por: Tapia-Galisteo, Antonio, et al.
Publicado: (2023)

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies
por: Ye, Baixin, et al.
Publicado: (2017)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
por: Tian, Zheng, et al.
Publicado: (2021)

Exosomes and pancreatic diseases: status, challenges, and hopes
por: Guo, Xiao-Yu, et al.
Publicado: (2019)

Radiation for hematologic malignancies: from cell killing to immune cell priming
por: Dabaja, Bouthaina, et al.
Publicado: (2023)

Erratum to: CAR T Cell Therapy for Hematological Malignancies
por: Yang, Xin, et al.
Publicado: (2021)

Hope against hope: exploring the hopes and challenges of rural female caregivers of persons with advanced cancer
por: Williams, Allison, et al.
Publicado: (2013)

Myeloid-derived suppressor cells in hematological malignancies: friends or foes
por: Lv, Meng, et al.
Publicado: (2019)

Metagenomic Next-Generation Sequencing for Diagnostically Challenging Mucormycosis in Patients with Hematological Malignancies
por: Zhang, Meng, et al.
Publicado: (2022)

Use of Telemedicine in Care of Hematologic Malignancy Patients: Challenges and Opportunities
por: Lloyd, Jennifer, et al.
Publicado: (2022)

Mesenchymal stem cells in suppression or progression of hematologic malignancy: current status and challenges
por: Lee, Myoung Woo, et al.
Publicado: (2019)

The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation
por: Wang, Limengmeng, et al.
Publicado: (2014)

The Landscape of Nucleic-Acid-Based Aptamers for Treatment of Hematologic Malignancies: Challenges and Future Directions
por: Wang, Si Chun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pq0oaf1bc41422b74ldvmhhpku